Curated News
By: NewsRamp Editorial Staff
August 21, 2024
Continuous Blood Glucose Monitoring: A Game-Changer for Diabetes Management
TLDR
- Continuous glucose monitoring market is projected to reach $44.6 billion by 2034, driving demand for more convenient management of diabetes.
- Continuous glucose monitoring (CGM) automatically tracks glucose 24/7 through a device worn on the body, providing real-time data for informed decisions.
- CGM devices offer a more convenient and less intrusive way to manage diabetes, potentially improving the quality of life for millions of people worldwide.
- Glucotrack, Inc. has developed a Continuous Blood Glucose Monitor (CBGM) that directly measures glucose in the blood, potentially transforming diabetes management.
Impact - Why it Matters
This news matters because diabetes is a chronic disease that affects millions of people globally. The development of a more accurate, discreet, and less burdensome CGM device has the potential to transform the lives of those with diabetes, offering a more convenient way to manage their condition.
Summary
Continuous glucose monitoring (CGM) offers a better alternative to traditional glucose meters for people with diabetes. With the market for CGM devices forecasted to reach $16.2 billion in 2024, the demand for more convenient ways to manage diabetes is evident. However, not all CGM devices are the same, each with their own limitations. Glucotrack, Inc. (NASDAQ: GCTK) has developed a Continuous Blood Glucose Monitor (CBGM) that aims to overcome these challenges by directly measuring glucose in the blood, providing a potentially less burdensome and more discreet monitoring solution.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Continuous Blood Glucose Monitoring: A Game-Changer for Diabetes Management
